🇺🇸 FDA
Pipeline program

611

SSGJ-611-COPD-III-01

Phase 3 small_molecule active

Quick answer

611 for Pulmonary Disease, Chronic Obstructive (COPD) is a Phase 3 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Pulmonary Disease, Chronic Obstructive (COPD)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials